<DOC>
	<DOCNO>NCT00330343</DOCNO>
	<brief_summary>This investigator initiate dose finding study design determine optimal dose naloxone prevent minimize common side effect induced opioids , namely itch , nausea , vomit . Male female inpatient Children ’ Center Johns Hopkins Hospital , great 6 less 18 year age acute , moderate severe pain , treat IVPCA morphine eligible inclusion study . Patients recruit study investigator prior initiation IVPCA therapy . The majority patient post operative patient , start therapy investigational drug Post Anesthesia Care Unit Pediatric Intensive Care Unit . We plan study 10 99 , male female patient 2 year period .</brief_summary>
	<brief_title>Optimal Dose Prophylactic Naloxone Reducing Opioid-Induced Side Effects Children/Adolescents</brief_title>
	<detailed_description>In patient age , opioids cornerstone management moderate severe pain . Regardless method administration , opioids produce unwanted side effect , include pruritus , nausea vomiting , constipation , urinary retention , cognitive impairment , tolerance , dependence , ( rarely ) respiratory depression . Based result previously complete randomized controlled trial , child adolescent moderate severe pain , routinely treated Children ’ Center Johns Hopkins Hospital low dose naloxone infusion ( 0.25 mcg/kg/HOUR ) whenever morphine intravenous patient control analgesia ( IVPCA ) parent/nurse control analgesia ( IVPNCA ) initiate . Although previous study show marked reduction incidence severity pruritus nausea , approximately third patient still experience side effect . The primary purpose study reduce failure rate determine optimal dose naloxone prevent opioid induced side effect determine dose find classic dose escalation method . Our second aim detemine pharmacokinetics morphine naloxone metabolites naloxone infusion rate attempt . We measure morphine , naloxone , metabolite use liquid chromatographic-electrospray ionization-tandem mass spectrometric method ( LC/MS/MS ) . Our final aim determine pharmacogenetics responder non-responders use DNA isolated patient blood . To accomplish need single blood collection patient currently treat IVPCA morphine low dose intravenous naloxone .</detailed_description>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Male female patient great 6 less 18 year age acute , moderate severe pain start treatment IVPCA morphine inpatient Children 's Center Johns Hopkins Hospital patient require concomitant benzodiazepine administration allergic opioids investigational drug trial within 1 month receive opioids 7 day study parent psychiatric illness impairs ability provide consent parent speak English</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>morphine</keyword>
	<keyword>naloxone</keyword>
	<keyword>pediatrics</keyword>
	<keyword>adverse effect</keyword>
	<keyword>pain</keyword>
</DOC>